StockVS

NYSE American · Biotechnology · USD

AEON Biopharma, Inc. (AEON) Stock Analysis

AEON Biopharma, Inc. (AEON) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

AEON

$0.24

−$0.01 (−5.49%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AEON with… →

AEON Key Statistics

As of Sep 4, 2026
Trading
Open
$0.26
Previous Close
$0.26
Day's Range
0.24–0.28
52-Week Range
0.18–1.45
Volume
758.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.65
Valuation
Market Cap
$12.01M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.55
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$39.22M−193.37%
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
49.88M
1-Year Return
−68.62%
Dividend and dates
Avg Volume
2.64M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AEON Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−78.09%
2025−97.17%
2024−92.50%
2023−28.43%

As of September 4, 2026.

AEON Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$39.22M
2024$0.00$42.01M
2022$0.00−$52.56M
2021$0.00−$55.64M
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00−$16.30M−$39.22M
2024$0.00−$27.82M$42.01M
2022$0.00−$48.43M−$52.56M
2021$0.00−$36.88M−$55.64M

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AEON Valuation vs Biotechnology Median

Median of 656 stocks
MetricAEONBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values AEON Biopharma, Inc. (AEON) at $12.01M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 8.

AEON last closed at $0.24 on September 4, 2026. That is −$0.01 (−5.49%) against the previous close. Over the past 52 weeks the price has ranged from $0.18 to $1.45. The latest close sits 36.16% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $39.22M. The reported profit margin is 0%. Trailing earnings per share are −4.55.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2021 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is −68.62%. Measured over 3 years, that is −91.41% a year compounded. The reported beta is 0.65. Daily returns over the trailing 3 years annualize to a volatility of 150.23%.

Growth & Income

The record shows no dividend for AEON.

The strongest complete calendar year on file is 2023 at −28.43%; the weakest is 2025 at −97.17%. Of the 3 complete calendar years on file, 0 finished higher. 2026 is still running; the price is −78.09% year to date.

Peer Comparison

AEON Biopharma, Inc. (AEON) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AEON Biopharma, Inc. AEON $12.01M
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. AEON Biopharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

View all Biotechnology stocks →

Popular Healthcare Stocks

View all Healthcare stocks →

About AEON Biopharma, Inc.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Visit website →